The company went public in December last year.
Total revenues stood at Rs 467 crore during the quarter under discussion when compared to Rs 483 crore during the previous quarter, the city-based company said in a statement.
"Prepayment of loans resulted interest cost reduction apart from reduction in cost of funds," it said.
"Laurus' growth march continues with broadening of the market in key APIs across new geographies and novel therapeutic areas," its CEO Satyanarayana Chava said here.
Laurus spent about Rs 315.5 crore towards capex during last year.
The total revenue of the drug maker in FY 17 rose 6.6 per cent to Rs 1892 crore as compared to Rs 1775 crore in FY 16 while PAT increased by 40 per cent to Rs 203 crore against Rs 148 crore during the previous year.
Disclaimer: No Business Standard Journalist was involved in creation of this content
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
